Table 5.
Main outcomes stratified for users of acenocoumarol and phenprocoumon
| Outcome | Acenocoumarol (n = 254) | Phenprocoumon (n = 71) | ||
|---|---|---|---|---|
| Protective effect of PDR | Adjusted OR (95%CI)a | P | Adjusted OR (95%CI)a | P |
| Co-trimoxazole | ||||
| PDR applied, INR >4.5 | 0.08 (0.01–0.70) | 0.022* | 0.16 (0.01–4.48) | >0.3b |
| PDR not applied | Reference | Reference | ||
| Risk of overanticoagulation | ||||
| PDR not applied | ||||
| Co-trimoxazole, INR >4.5 | 4.40 (1.15–16.8) | 0.030* | 3.83 (0.55–26.7) | 0.18 |
| Other antibiotics | Reference | Reference | ||
| % Time within or under TR | Mean difference (95%CI) | Mean difference (95%CI) | ||
| Co-trimoxazole, % time within TR | −22.1 (−39.1 to –5.0) | 0.011* | −21.4 (−49.4 to 6.6) | 0.13 |
| Co-trimoxazole, % time under TR | 20.3 (10.9–29.7) | <0.001* | 22.6 (5.7–39.5) | 0.010* |
| Other antibiotics | Reference | Reference | ||
| Co-trimoxazole, PDR applied | ||||
| % time under TR | 9.1 (3.0–15.1) | 0.004* | −6.7 (−23.0 to 9.6) | 0.42 |
| Other antibiotics | ||||
| PDR applied + PDR not applied | Reference | Reference | ||
*Statistically significant difference at P ≤ 0.05
aAdjusted for differences in fever as indicated by patient, age, sex and target therapeutic range
bAdjustment not applied because the number of patients with INR >4.5 was zero; OR was calculated by increasing the values of each of the cells of the crosstable by 0.5